E-Cadherin Expression in Endometrial Carcinoma
DOI:
https://doi.org/10.21276/apalm.3221Keywords:
Endometrial carcinoma, E-cadherin expression, histological subtypes, Stage, GradeAbstract
Background
In this study, we wanted to determine the proportion of negative E-cadherin expression in endometrial carcinoma cases received in the Department of Pathology and evaluate the E-cadherin expression in different histological subtypes of endometrial carcinoma.
Methods
This was a cross-sectional study conducted over one year in the Department of Pathology, Government Medical College, Thiruvananthapuram, Kerala. 52 specimens histopathologically diagnosed as endometrial carcinoma in the Department of Pathology, were studied. Age, histological subtype, grade, stage and E-cadherin staining were recorded. Data were entered into an Excel sheet and analysed with SPSS.
Result
Clinicopathological features of were studied and the median age group of the patients was between 51-60 years. The majority of cases were of endometrioid type and presented at stage IA (69.2 %). Negative E cadherin expression was seen more commonly in Type II endometrial carcinomas (50 & 33.3 % of serous and clear cell carcinoma respectively). Among the Type I carcinoma, grade 3 tumours showed the most proportion of negative E-cadherin staining pattern (33.3 %).
Conclusion:
The study concluded that most of the tumours occurred in the postmenopausal age group and the majority of cases were in stage IA, most cases were of endometrioid type. E-cadherin was lost most commonly in high-grade endometrioid carcinoma and Type 2 carcinomas. Among the 3 grades of endometrioid carcinoma, grade 3 (33.3 %) had the highest proportion of negative staining and grade 1 had the highest proportion of positive staining characteristics. (57.1 %).
References
World Research Cancer Fund International. Available from: http://www.wcrf.org
Almadani N, Thompson EF, Tessier-Cloutier B, et al. An update of molecular pathology and shifting systems of classification in tumors of female genital tract. Diagn Histopathol. 2020;26(6):278-88.
Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016;3:14.
World Health Organization. Classification of tumors of the female genital tract. 2020.
Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecularâ€based classification for endometrial cancers. Br J Cancer. 2015;113(2):299-310.
Trana AQ, Gehrig P. Recent advances in endometrial cancer. F1000Res. 2017;6:81.
Sakuragi N, Nishiya M, Ikeda K, et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion. Gynecol Oncol. 1994;53(2):183-9.
Saito T, Nishimura M, Yamasaki H, et al. Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinoma. Cancer. 2003;97(4):1002-9.
Bharatnur S, Kustagi P, Krishnamohan D. Endometrial carcinoma in a young woman: "30 is Not Immune". J Obstet Gynaecol India. 2011;61(6):686-8.
Yalta T, Atay L, Atalay F, et al. E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas. J Int Med Res. 2009;37(1):163-8.
Balasubramaniam G, Sushama S, Rasika B, et al. Hospital-based study of endometrial cancer survival in Mumbai, India. Asian Pac J Cancer Prev. 2013;14(2):977-80.
Mell LK, Meyer JJ, Tretiakova M, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004;10(16):5546-53.
Park JH, Lee BI, Song ES, et al. Hypermethylation of E-cadherin in endometrial carcinoma. J Gynecol Oncol. 2008;19(4):241-5.
Ascaño JJ, Frierson H, Moskaluk CA, et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol. 2001;14(10):942-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Geethika P Ullas, Sheela K M
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).